Noble Financial Capital Markets Conference

January 17th-20th, 2016

Club Med, South Florida

For the third year in a row, Noble Financial Group will take over all of Club Med's 220 acres to host its "destination" investor conference. NobleCon12, taking place January 17-20, 2016, will feature a lineup that includes 150 presenting companies (most public, with a selection of private companies) who will showcase their innovations, operations and potential to more than 350 qualified investors looking for new investment ideas. Attendees stay onsite at the beautiful Club Med, getting the most out of company presentations, keynote speakers, dynamic panels, social activities and networking. For more information visit, Inc. (FLWS), Inc. (NASDAQ: FLWS) is a florist and gift shop offering a wide range of gifts such as fresh flowers and plants, gift baskets, gourmet foods, confections, candles, balloons, stuffed animals and more. The company also owns and operates BloomNet® international floral wire service, the Popcorn Factory®, Cheryl's® cookies and baked gifts, Fannie May® confection brands, Stock Yards® steaks and chops,®, and Celebrations® party store. For more information, visit the company's website at

Aequus Pharmaceuticals, Inc. (AQSZF)

Aequus Pharmaceuticals, Inc. (OTC: AQSZF) is a rapidly growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus' management team has a proven track record of managing clinical development, regulatory approval, product launches, and marketing products either directly or through partnerships. Aequus' commercial pipeline is focused on highly specialized therapeutic areas, including neurology, ophthalmology and transplant. The development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. For more information, visit the company's website at

Agile Therapeutics, Inc. (AGRX)

Agile Therapeutics, Inc. (NASDAQ: AGRX) is a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products that provide women with greater convenience and facilitate compliance. The company's lead product candidate, Twirla®, is a once-weekly prescription contraceptive patch currently in phase III clinical development. Twirla is based on Agile's proprietary transdermal patch technology, Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability. For more information, visit the company's website at

Avino Silver & Gold Mines Ltd. (ASM)

Avino Silver & Gold Mines Ltd. (NYSE: ASM) is a Vancouver-based mining and exploration firm. Founded in 1968, Avino's mission is to create shareholder value through profitable organic growth at the historic Avino property near Durango, Mexico, and the Bralorne property in southwestern British Columbia, Canada. The company is committed to handling all business activities in an environmentally-responsible and cost-effective manner while contributing to the well-being of the communities in which it operates. For more information, visit the company's website at

BioSig Technologies, Inc. (BSGM)

BioSig Technologies, Inc. (OTC: BSGM) is a medical device company that is developing a proprietary technology platform designed to improve the rapidly growing $3 billion electrophysiology (EP) marketplace. Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig is preparing to commercialize its PURE EP System. PURE EP is designed to improve the clarity of clinical signals available for EP studies and cardiac catheter ablation. It is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system. For more information, visit the company's website at

Cachet Financial Solutions, Inc. (CAFN)

Remote deposit capture (RDC) and mobile money technologies are changing business and personal banking forever. Cachet Financial Solutions, Inc. (OTC: CAFN), a leading provider of cloud-based, SaaS financial solutions, helps financial institutions of all sizes to leverage its sophisticated RDC and mobile money solutions to create new revenue streams, foster deeper customer relationships and gain a competitive edge. Since its founding in early 2010, Cachet has quickly grown into a technology leader and trusted partner of some of the world's largest and most respected financial organizations. For more information, visit the company's website at

Caladrius Biosciences, Inc. (CLBS)

Caladrius Biosciences, Inc. (NASDAQ: CLBS), through its wholly owned subsidiary, PCT, is a leading development and manufacturing partner to the cell therapy industry. Caladrius works with its clients to overcome the fundamental challenges presented by cell therapy manufacturing by providing a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support. Around this core expertise, Caladrius strategically develops product candidates, which currently include an innovative therapy for type I diabetes based on a proprietary platform technology for immunomodulation. For more information, visit the company's website at

ContraVir Pharmaceuticals, Inc. (CTRV)

ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV) is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. ContraVir's lead candidate, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is currently in phase 3 clinical development. ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir DF (Viread), for the Hepatitis B virus ("HBV") in phase 2 clinical studies. For more information, visit the company's website at

Corvus Gold Inc. (CORVF)

Corvus Gold Inc. (OTC: CORVF) is a North American gold exploration and development company focused on its near-term gold-silver mining project at North Bullfrog, Nevada. In addition Corvus Gold controls a number of other North American exploration properties representing a spectrum of gold, silver and copper projects. The company is committed to building shareholder value through new discoveries and the expansion of those discoveries to maximize share price leverage in a recovering gold and silver market. The company was incorporated in 2010 and is headquartered in Vancouver, Canada. For more information, visit the company's website at

Cynapsus Therapeutics, Inc. (CYNA)

Cynapsus Therapeutics, Inc. (NASDAQ: CYNA) is a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand turning ON of debilitating OFF episodes associated with Parkinson's disease (PD). The company's lead product candidate, APL-130277, is a sublingual formulation of apomorphine hydrochloride, or apomorphine. Cynapsus has initiated its phase 3 clinical program for APL-130277, and intends to submit a new drug application in 2016. For more information, visit the company's website at

Energy Fuels, Inc. (UUUU)

Energy Fuels, Inc. (NYSE: UUUU) is an integrated U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. Energy Fuels operates two of America's key uranium production centers: the White Mesa Mill in Utah and the Nichols Ranch Processing Facility in Wyoming. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today and has a licensed capacity of over 8 million pounds of U3O8 per year. The Nichols Ranch Processing Facility, acquired in the company's acquisition of Uranerz Energy Corporation, has a licensed capacity of 2 million pounds of U3O8 per year. For more information, visit the company's website at

Entravision Communications Corp. (EVC)

Entravision Communications Corp. (NYSE: EVC) is a diversified media company serving Latino audiences and communities with an integrated platform of solutions and services that includes television, radio, digital media and data analytics to reach Latino audiences across the U.S. and Latin America. Entravision has 58 primary television stations, including in 20 of the nation's top 50 Latino markets, and is the largest affiliate group of both the top-ranked Univision television network and Univision's UniMas network. Entravision also operates one of the nation's largest groups of primarily Spanish-language radio stations, consisting of 49 owned and operated radio stations, and Entravision Solutions. For more information, visit the company's website at

EyeGate Pharmaceuticals, Inc. (EYEG)

EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) is a late-stage specialty pharmaceutical and drug delivery company focused on developing and commercializing therapeutics and drug delivery mechanisms for treating diseases of the eye. EyeGate's technology addresses two of the most prevalent issues in ophthalmic care: the existing lack of patient adherence and patient safety. EyeGate is committed to advancing its delivery technology and therapeutic candidates with a goal of bringing new, potentially superior treatment options to patients who will most likely benefit. For more information, visit the company's website at

Fusion Telecommunications International, Inc. (FSNN)

Fusion Telecommunications International, Inc. (NASDAQ: FSNN), in concert with its subsidiaries, provides cloud communications, cloud connectivity, cloud computing, and managed cloud-based solutions to small, medium and large businesses worldwide. The company also offers voice services to communications carriers. Fusion Telecommunications operates in two segments: Business Services and Carrier Services. For more information, visit the company website at

Galena Biopharma, Inc. (GALE)

Galena Biopharma, Inc. (NASDAQ: GALE) is developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care. Galena's development portfolio ranges from mid- to late-stage clinical assets, including a robust immunotherapy program led by NeuVax (nelipepimut-S) currently in an international, phase III clinical trial. The company's commercial drugs include Abstral (fentanyl) Sublingual Tablets and Zuplenz (ondansetron) Oral Soluble Film. For more information, visit the company's website at

Guidance Software, Inc. (GUID)

Guidance Software, Inc. (NASDAQ: GUID) is the maker of EnCase, the gold standard in digital investigations and endpoint data security. With this technology, Guidance Software provides a mission-critical foundation of applications that have been deployed on an estimated 25 million endpoints and work in concert with other leading enterprise technologies from companies such as Cisco, Intel, Box, Dropbox, Blue Coat Systems, and LogRhythm. For more information, visit the company's website at

Implant Sciences Corp. (IMSC)

Implant Sciences Corp. (OTC: IMSC) is a leader in advancing trace detection capabilities to address evolving security problems. Implant Sciences' non-radioactive ion mobility spectrometry systems have been deployed in more than 50 nations worldwide for aviation security, infrastructure protection, mass transit security, military operations, VIP protection, and corporate security. The QS-B220 desktop explosives and drugs trace detector is the first ETD to meet the standards of both TSA and ECAC. The QS-B220 uses Ion Mobility Spectrometry to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives as well as illicit drugs. For more information, visit the company's website at

Innodata, Inc. (INOD)

Innodata, Inc. (NASDAQ: INOD) is a leading services company providing content solutions, data analytics and related services to publishers, information providers, and enterprises. Innodata provides services, products and solutions that its clients use to create, manage and distribute digital information. In response to market demand for transformation from print publishing to online publishing, from search-based information products to workflow-based information products, and from web-based distribution to multiple-channel distribution—including mobile, tablet and eReading devices—Innodata is continuously adopting new strategies, technologies and processes. For more information, visit the company's website at

Merit Medical Systems, Inc. (MMSI)

Merit Medical Systems, Inc. (NASDAQ: MMSI) is a worldwide company engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology, radiology and endoscopy. Its primary products consist of inflation devices used in angioplasty and stent placement; diagnostic and therapeutic catheters used for various procedures in cardiology and radiology; diagnostic and hydrophilic products used to manage and monitor the administration of contrast media and other fluid solutions; thrombolytic catheters and fluid dispensing systems; and embolotherapeutic products for the treatment of uterine fibroids, hypervascularized tumors, and arteriovenous malformations. For more information, visit the company's website at

Naked Brand Group, Inc. (NAKD)

Naked Brand Group, Inc. (OTC: NAKD) was founded to create a new standard for how products worn close to the skin fit, feel and function. Naked's strong and growing retail footprint for its innovative and luxurious men's innerwear products includes online and department stores such as Nordstrom, Hudson Bay, Holt Renfrew,, and many more. In June 2015, Naked announced a strategic partnership with NBA Miami HEAT star Dwyane Wade, who joined the company's advisory board and will serve as creative director for a signature collection of men's innerwear launching 2016. For more information, visit the company's website at

NephroGenex, Inc. (NRX)

NephroGenex, Inc. (NASDAQ: NRX) is an innovator in the development of drugs to treat kidney disease, with a first indication in diabetic nephropathy. NephroGenex has been pioneering the development of PYRIDORIN (pyridoxamine dihydrochloride), a late stage compound to treat diabetic patients with this slow-developing but potentially deadly disease. Pyridorin has the potential to slow or stabilize the progression to end-stage renal disease by inhibiting the formation of advanced glycation end products that have been implicated in the development of diabetic nephropathy. For more information, visit the company's website at

Nuvo Research, Inc. (NRIFF)

Nuvo Research, Inc. (OTC: NRIFF) is a life sciences company with a diverse portfolio of products and technologies. In September, Nuvo announced that it plans to split Nuvo into two separate, publicly traded companies. Under the proposed plan, one company, to be known as Nuvo Pharmaceuticals Inc., will be a commercial healthcare company that will own the company's Pennsaid and Pennsaid 2% franchises and related assets. The other company, to be known as Crescita Therapeutics Inc., will be a development company that will own the company's existing drug development business including its pipeline of product candidates. For more information, visit the company's website at

O2Micro International Ltd. (OIIM)

Founded in April 1995, O2Micro International Ltd. (NASDAQ: OIIM) designs, develops and markets innovative power management components for the Computer, Consumer, Industrial, Automotive and Communications markets. Its strengths lie in its system architecture knowledge in power management, fast time-to-market, strong customer relationships, and mixed signal engineering Integrated Circuit (IC) capabilities. The strength in mixed signal engineering is due to O2Micro's talented teams of analog and digital engineers. With offices worldwide, the company is staffed by a team of industry veterans with a successful track record and proven expertise in design, marketing, and operations. For more information, visit the company's website at

OmniComm Systems, Inc. (OMCM)

OmniComm Systems, Inc. (OTC: OMCM) is a leading strategic software solutions provider to the life sciences industry. OmniComm Systems is dedicated to helping the world's pharmaceutical; biotechnology; contract research organizations; diagnostic and device firms; and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit the company's website at

Pacific Energy Development Corp. (PED)

Pacific Energy Development Corp. (NYSE: PED) engages in the acquisition, exploration, development, and production of oil and natural gas shale plays in the U.S. The company's principal asset is Denver-Julesberg (D-J) Basin asset comprising approximately 26,990 net acres located in the Weld and Morgan Counties, Colorado. As of February 5, 2015, it had interests in 53 gross wells; and produced approximately 994 barrels of oil equivalent per day. Pacific Energy has strategic alliances with Golden Globe Energy (US), LLC; MIE Holdings Corporation; and South Texas Reservoir Alliance, LLC. The company was founded in 2011 and is headquartered in Danville, California. For more information, visit the company's website at

Palatin Technologies, Inc. (PTN)

Palatin Technologies, Inc. (NYSE: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The company's primary product in development is bremelanotide for the treatment of female sexual dysfunction. In addition, Palatin has development programs or drug candidates for erectile dysfunction, pulmonary diseases, heart failure, obesity, inflammatory diseases and dermatologic diseases. For more information, visit the company's website at

Peregrine Pharmaceuticals, Inc. (PPHM)

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies focused on the treatment and diagnosis of cancer. Peregrine is pursuing multiple clinical programs in cancer with its lead product candidate, bavituximab, and novel brain cancer agent Cotara. Peregrine also has in-house cGMP manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., which provides development and biomanufacturing services for Peregrine and outside customers. Bavituximab in combination with chemotherapy has demonstrated promising signs of anti-tumor activity and survival trends in patients with non-small cell lung cancer (NSCLC) and advanced breast cancer. For more information, visit the company's website at

Remark Media, Inc. (MARK)

Remark Media, Inc. (NASDAQ: MARK) operates as a digital media company in the U.S., China and Brazil. Remark Media owns and operates digital media properties, such as websites and applications for mobile devices that provide digital media experiences in multiple content verticals, including personal finance, young adult lifestyle, travel, education and entertainment. The company operates website, which provides content for young adults that shares stories of financial success and failure; US Tax Center at that provides users with access to U.S. tax-related information and services; and and websites that assist taxpayers with filing business and personal tax extensions with the IRS. For more information, visit the company's website at

SeaChange International, Inc. (SEAC)

Enabling its customers to deliver billions of premium video streams across a matrix of pay-TV, OTT and mobile platforms, SeaChange (NASDAQ: SEAC) empowers service providers, content owners and brand advertisers to entertain audiences, engage consumers and expand business opportunities. As a three-time Emmy award-winning organization with over 20 years of experience, SeaChange gives media businesses the content management, delivery, measurement and analytics capabilities they need to craft an individualized branded experience for every viewer that sets the pace for quality and value worldwide. For more information, visit the company's website at

Social Reality, Inc. (SCRI)

Social Reality, Inc. (OTC: SCRI) provides tools to automate the digital advertising market. The company builds technologies and leverages partner technologies that service social media and the real time bidding markets. It offers display, mobile, video and email advertising inventory to brands and advertising agencies. The company also provides managed advertising services utilizing data from platforms, including Facebook, Yahoo, LinkedIn and Google to optimize digital advertising for its customers. In addition, it creates applications as custom programs and builds them on a campaign-by-campaign basis, as well as offers them on a managed or self-service subscription basis through its GroupAd platform. For more information, visit the company's website at

Telkonet, Inc. (TKOI)

Telkonet, Inc. (OTC: TKOI) offers EcoSmart energy management technology as well as EthoStream high-speed Internet access solutions. Both product lines satisfy Telkonet's commitment to product innovation and technological expertise, and have been installed in several hundred thousand rooms worldwide. Telkonet's EcoSmart products, along with the EcoCentral management platform, reduce energy consumption, HVAC runtime and utility costs in most building environments. All EcoSmart systems feature Recovery Time, technology designed to maximize energy efficiency without compromising room comfort. EcoSmart enables customers to take complete control of energy management with cutting-edge technology, real-time analytics, and participation in demand/response programs. For more information, visit the company's website at

VBI Vaccines, Inc. (VBIV)

VBI Vaccines, Inc. (NASDAQ: VBIV) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI's eVLP vaccine platform allows for the design of enveloped ("e") virus-like particle ("VLP") vaccines that closely mimic the target virus. The company's lead eVLP asset is a prophylactic Cytomegalovirus ("CMV") vaccine; VBI has initiated work for GMP manufacturing of its CMV candidate for use in formal preclinical and phase I trials. The company's second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. For more information, visit the company's website at

Contact us: 212.418.1217